Dr Reddy's in pact with Fujifilm to develop, manufacture Covid-19 drug Favipiravir - Times of India

HYDERABAD: Pharma major Dr Reddy's Laboratories Ltd has joined hands with Fujifilm Toyama Chemical Co Ltd, which is part of Fujifilm Corporation, and Global Response Aid (GRA) for the development, manufacture and sales of potential Covid-19 treatment drug Favipiravir under the Avigan brand name.
Under the tripartite agreement, Dr Reddy’s will get exclusive rights to manufacture Fujifilm’s Avigan tablets. Fujifilm will also grant Dr Reddy’s the right to use Avigan’s patents of formulation and manufacturing method, Dr Reddy's said.
The Japanese player has also granted Dr Reddy’s and GRA the rights to develop, sell and distribute Avigan across the world, except Japan, China and Russia. Fujifilm will receive an upfront license fee and royalties on sales from Dr Reddy’s and GRA.
Dr Reddy’s said it will establish a setup for manufacturing drugs of the same quality standards as Avigan and utilize GRA’s global sales network to supply the manufactured drugs swiftly and in a stable manner.
The pact also gives Dr Reddy’s exclusive rights for the development, sale and distribution of Avigan in India.
As part of the agreement, Fujifilm will provide Dr Reddy’s and GRA data on Avigan’s preclinical and clinical studies, which the two players can use for clinical studies targeting Covid-19 in regions where infection has been spreading.
The Fujifilm Group is currently conducting a clinical study on Avigan targeting Covid-19 patients in Japan and the US, and is working on ramping up the drug’s production by partnering with domestic and overseas players.

Let's block ads! (Why?)

Read Again https://timesofindia.indiatimes.com/business/india-business/dr-reddys-in-pact-with-fujifilm-to-develop-manufacture-covid-19-drug-favipiravir/articleshow/76732491.cms

Bagikan Berita Ini